Literature DB >> 12580222

Inhaled nitric oxide and pulmonary vasoreactivity.

M Aranda1, R G Pearl.   

Abstract

Inhaled nitric oxide is a ubiquitous molecule which is produced endogenously and is also found in air pollution and in cigarette smoke. After describing the chemistry of NO, we review its history from the first description in 1980 to the current clinical indications. The biosynthesis of NO, its effects on pulmonary vasoreactivity, and the administration of inhaled NO will be described. The indications, uses, and side effects of inhaled NO are discussed with an emphasis on withdrawal of NO therapy, specifically the "rebound" phenomenon. Possible drug interactions are listed. Inhaled nitric oxide is here to stay, and future studies will provide more information on its therapeutic dose, duration and potential toxicity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 12580222     DOI: 10.1023/a:1011468005527

Source DB:  PubMed          Journal:  J Clin Monit Comput        ISSN: 1387-1307            Impact factor:   2.502


  49 in total

Review 1.  Inhaled nitric oxide: basic biology and clinical applications.

Authors:  W Steudel; W E Hurford; W M Zapol
Journal:  Anesthesiology       Date:  1999-10       Impact factor: 7.892

2.  Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn.

Authors:  D L Wessel; I Adatia; L J Van Marter; J E Thompson; J W Kane; A R Stark; S Kourembanas
Journal:  Pediatrics       Date:  1997-11       Impact factor: 7.124

3.  The use of phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide.

Authors:  S al-Alaiyan; A al-Omran; D Dyer
Journal:  Intensive Care Med       Date:  1996-10       Impact factor: 17.440

4.  Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group.

Authors:  D Davidson; E S Barefield; J Kattwinkel; G Dudell; M Damask; R Straube; J Rhines; C T Chang
Journal:  Pediatrics       Date:  1998-03       Impact factor: 7.124

5.  Inhalation of nitric oxide as a life-saving therapy in a patient after pulmonary embolectomy.

Authors:  P Schenk; T Pernerstorfer; C Mittermayer; A Kranz; M Frömmel; T Birsan; K Ratheiser
Journal:  Br J Anaesth       Date:  1999-03       Impact factor: 9.166

6.  Combination of inhaled nitric oxide and intravenous prostacyclin for successful treatment of severe pulmonary hypertension in a patient with acute respiratory distress syndrome.

Authors:  R Kuhlen; E Walbert; P Fränkel; S Thaden; W Behrendt; R Rossaint
Journal:  Intensive Care Med       Date:  1999-07       Impact factor: 17.440

7.  Inhaled nitric oxide improves hemodynamics in patients with acute pulmonary hypertension after high-risk cardiac surgery.

Authors:  J R Beck; L B Mongero; R M Kroslowitz; A F Choudhri; J M Chen; J J DeRose; M Argenziano; A J Smerling; M C Oz
Journal:  Perfusion       Date:  1999-01       Impact factor: 1.972

8.  Pulmonary hypertensive crises following surgery for congenital heart defects in young children.

Authors:  R A Hopkins; C Bull; S G Haworth; M R de Leval; J Stark
Journal:  Eur J Cardiothorac Surg       Date:  1991       Impact factor: 4.191

9.  Pulmonary performance of elderly normal subjects and subjects with chronic obstructive pulmonary disease exposed to 0.3 ppm nitrogen dioxide.

Authors:  P E Morrow; M J Utell; M A Bauer; A M Smeglin; M W Frampton; C Cox; D M Speers; F R Gibb
Journal:  Am Rev Respir Dis       Date:  1992-02

10.  Quantitation of nitrotyrosine levels in lung sections of patients and animals with acute lung injury.

Authors:  I Y Haddad; G Pataki; P Hu; C Galliani; J S Beckman; S Matalon
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.